Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein

K. A. Lears, J. J. Parry, R. Andrews, K. Nguyen, T. J. Wadas, B. E. Rogers

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Suicide gene therapy is a process by which cells are administered a gene that encodes a protein capable of converting a nontoxic prodrug into an active toxin. Cytosine deaminase (CD) has been widely investigated as a means of suicide gene therapy owing to the enzyme's ability to convert the prodrug 5-fluorocytosine (5-FC) into the toxic compound 5-fluorouracil (5-FU). However, the extent of gene transfer is a limiting factor in predicting therapeutic outcome. The ability to monitor gene transfer, non-invasively, would strengthen the efficiency of therapy. In this regard, we have constructed and evaluated a replication-deficient adenovirus (Ad) containing the human somatostatin receptor subtype 2 (SSTR2) fused with a C-terminal yeast CD gene for the non-invasive monitoring of gene transfer and therapy. The resulting Ad (AdSSTR2-yCD) was evaluated in vitro in breast cancer cells to determine the function of the fusion protein. These studies demonstrated that both the SSTR2 and yCD were functional in binding assays, conversion assays and cytotoxicity assays. In vivo studies similarly demonstrated the functionality using conversion assays, biodistribution studies and small animal positron-emission tomography (PET) imaging studies. In conclusion, the fusion protein has been validated as useful for the non-invasive imaging of yCD expression and will be evaluated in the future for monitoring yCD-based therapy.

Original languageEnglish
Pages (from-to)215-221
Number of pages7
JournalCancer gene therapy
Issue number4
StatePublished - Mar 25 2015


Dive into the research topics of 'Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein'. Together they form a unique fingerprint.

Cite this